NO20061562L - Anvendelse av 1- [4-(5-cyanindol-3yl)butyl ] -4-(2-karbamoylbenzofuran-5-yl)-piperazin og dets fysiologisk akseptable salter - Google Patents

Anvendelse av 1- [4-(5-cyanindol-3yl)butyl ] -4-(2-karbamoylbenzofuran-5-yl)-piperazin og dets fysiologisk akseptable salter

Info

Publication number
NO20061562L
NO20061562L NO20061562A NO20061562A NO20061562L NO 20061562 L NO20061562 L NO 20061562L NO 20061562 A NO20061562 A NO 20061562A NO 20061562 A NO20061562 A NO 20061562A NO 20061562 L NO20061562 L NO 20061562L
Authority
NO
Norway
Prior art keywords
carbamoylbenzofuran
piperazine
cyanindol
butyl
physiologically acceptable
Prior art date
Application number
NO20061562A
Other languages
English (en)
Other versions
NO324230B1 (no
Inventor
Henning Bottcher
Gerd Bartoszyk
Christoph Seyfried
Christoph Van Amsterdam
Ewen Sedman
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8238153&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20061562(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of NO20061562L publication Critical patent/NO20061562L/no
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NO324230B1 publication Critical patent/NO324230B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

¦4-(2-karbamoylbenzofuran-5-yl)-piperazin l-[4-(5-cyanindol-3-yl)butyl]-4-(2-karbamoylbenzofiiran-5-yl)-piperazin eller et fysiologisk akseptabelt salt derav anvendes til fremstiUing av et medikament for behandling av bipolare forstyrrelser, mani, demens, stoffrelaterte forstyrrelser, seksuelle dysfimksjoner, spiseforstyrrelser, fedme, anoreksi og fibromyalgi. Et foretrukket salt er l-[4-(5-cyanindol3-yl)butyl]-4-(2-karbamoylbenzofiiran-5-yl)- piperazinhydroklorid.
NO20061562A 1999-05-27 2006-04-06 Anvendelse av 1- [4-(5-cyanindol-3yl)butyl ]-4-(2-karbamoylbenzofuran-5-yl)-piperazin og dets fysiologisk akseptable salter til fremstilling av medikamenter for behandling av bipolare forstyrrelser og mani NO324230B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99109295 1999-05-27
PCT/EP2000/004376 WO2000072832A2 (en) 1999-05-27 2000-05-16 Novel use of 1-[4-(cyanoindol-3yl)butyl]-4-(carbamoyl-benzofuran-5yl)-piperazine and its physiologically acceptable salts

Publications (2)

Publication Number Publication Date
NO20061562L true NO20061562L (no) 2001-11-26
NO324230B1 NO324230B1 (no) 2007-09-10

Family

ID=8238153

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20015746A NO322120B1 (no) 1999-05-27 2001-11-26 Anvendelse av 1-[4-(5-cyanindol-3-yl)butyl]-4-(2-karbamoylbenzofuran-5-yl)-piperazin og dets fysiologisk akseptable salter til fremstilling av medikamenter for behandling av angstforstyrrelser av undertype
NO20061562A NO324230B1 (no) 1999-05-27 2006-04-06 Anvendelse av 1- [4-(5-cyanindol-3yl)butyl ]-4-(2-karbamoylbenzofuran-5-yl)-piperazin og dets fysiologisk akseptable salter til fremstilling av medikamenter for behandling av bipolare forstyrrelser og mani

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20015746A NO322120B1 (no) 1999-05-27 2001-11-26 Anvendelse av 1-[4-(5-cyanindol-3-yl)butyl]-4-(2-karbamoylbenzofuran-5-yl)-piperazin og dets fysiologisk akseptable salter til fremstilling av medikamenter for behandling av angstforstyrrelser av undertype

Country Status (31)

Country Link
US (4) US6900212B1 (no)
EP (3) EP1410800B1 (no)
JP (2) JP4884588B2 (no)
KR (1) KR100683367B1 (no)
CN (3) CN101869565A (no)
AR (1) AR024112A1 (no)
AT (3) ATE438399T1 (no)
AU (1) AU771778B2 (no)
BR (1) BR0010948A (no)
CA (3) CA2615271C (no)
CY (2) CY1105750T1 (no)
CZ (1) CZ295623B6 (no)
DE (3) DE60009697T2 (no)
DK (3) DK1410800T3 (no)
ES (3) ES2219342T3 (no)
HK (1) HK1048444B (no)
HU (1) HU229059B1 (no)
IL (2) IL146707A0 (no)
MX (1) MXPA01012172A (no)
MY (1) MY135627A (no)
NO (2) NO322120B1 (no)
PL (3) PL199516B1 (no)
PT (3) PT1736158E (no)
RU (1) RU2237477C2 (no)
SI (2) SI1185272T1 (no)
SK (1) SK287851B6 (no)
TR (1) TR200103361T2 (no)
TW (1) TW518218B (no)
UA (1) UA74337C2 (no)
WO (1) WO2000072832A2 (no)
ZA (1) ZA200110485B (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW518218B (en) * 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
UA76130C2 (en) * 2000-11-20 2006-07-17 Merck Patent Gmbh Use of compounds combining properties of selective inhibitors of serotonin re-uptake and agonists of 5-ht1a receptor for treatment of irritable bowel syndrome
DE10112151A1 (de) 2001-03-14 2002-09-19 Merck Patent Gmbh Substituierte Benzofuran-2-carbonsäureamide
UA76758C2 (uk) 2001-06-19 2006-09-15 Мерк Патент Гмбх Поліморфні форми гідрохлориду 1-'4-(5-ціаноіндол-3-іл)бутил-4-(2-карбамоїлбензофуран-5-іл)піперазину
DE10217006A1 (de) * 2002-04-16 2003-11-06 Merck Patent Gmbh Substituierte Indole
DE10305739A1 (de) * 2003-02-11 2004-08-19 Merck Patent Gmbh Benzofuranderivate
US20040192730A1 (en) * 2003-03-13 2004-09-30 Dynogen Pharmaceuticals, Inc. Methods of using compounds with combined 5-HT1A and SSRI activities as-needed to treat sexual dysfunction
US7893261B2 (en) 2004-03-26 2011-02-22 Baylor University Serotonin reuptake inhibitors
KR20090010092A (ko) 2006-05-30 2009-01-28 아스트라제네카 아베 Ｄｇａｔ1 억제제로서의 1,3,4-옥사디아졸 유도체
JP5662803B2 (ja) 2007-12-20 2015-02-04 アストラゼネカ アクチボラグ Ｄｇａｔ１阻害剤としてのカルバモイル化合物１９０
MX2011014018A (es) 2009-06-19 2012-02-22 Astrazeneca Ab Pirazincarboxamidas como inhibidores de dgati.
WO2011055944A2 (en) * 2009-11-06 2011-05-12 Sk Holdings Co., Ltd. Methods for treating fibromyalgia syndrome
KR101783632B1 (ko) 2009-11-06 2017-10-10 에스케이바이오팜 주식회사 주의력 결핍/과잉행동 장애(ａｄｈｄ)의 치료 방법
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
TWI577377B (zh) * 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
EP2688884A1 (en) 2011-03-20 2014-01-29 Cadila Healthcare Limited Amorphous form of vilazodone hydrochloride and process for its preparation
CN102949364A (zh) * 2011-08-30 2013-03-06 天津药物研究院 一种含有效成分盐酸维拉佐酮的缓释片
EP2861586A4 (en) 2012-06-13 2015-11-11 Apotex Inc FORMS OF VILAZODONE AND METHODS OF PREPARATION THEREOF
CN102860993A (zh) * 2012-10-16 2013-01-09 北京诚创思达医药科技有限公司 一种盐酸维拉唑酮快速释放片剂及其制备方法
WO2014064715A2 (en) 2012-10-22 2014-05-01 Cadila Healthcare Limited Amorphous form of vilazodone hydrochloride and process for preparing thereof
CN102977083A (zh) * 2012-12-17 2013-03-20 南京海纳医药科技有限公司 1-[4-(5-氰基吲哚-3-基)丁基]-4-(2-氨甲酰-苯并呋喃-5-基)-哌嗪盐酸盐的新晶型xⅶ及其制备方法
HRP20240812T1 (hr) 2013-01-22 2024-09-27 Vistagen Therapeutics, Inc. Oblici doziranja i terapijska primjena l-4-klorokinurenina
EP2824104A1 (en) 2013-07-12 2015-01-14 Sandoz AG Process for the preparation of form III of Vilazodone hydrochloride
JP2018521007A (ja) * 2015-05-22 2018-08-02 ヴィスタゲン セラピューティクス、インコーポレイテッド Ｌ−４−クロロキヌレニンの治療的使用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2672052B1 (fr) * 1991-01-28 1995-05-24 Esteve Labor Dr Derives d'aryl (ou heteroaryl)-piperazinyl-alkyl-azoles, leur preparation et leur application en tant que medicaments.
SE9201239D0 (sv) * 1992-04-21 1992-04-21 Kabi Pharmacia Ab Agents for treating substance abuse disorders
DE4333254A1 (de) 1993-09-30 1995-04-06 Merck Patent Gmbh Piperidine und Piperazine
GB9406857D0 (en) * 1994-04-07 1994-06-01 Sandoz Ltd Improvements in or relating to organic compounds
DE19514567A1 (de) * 1995-04-20 1996-10-24 Merck Patent Gmbh Benzofurane
US5763457A (en) * 1995-11-13 1998-06-09 Eli Lilly And Company Method for treating anxiety
US5914394A (en) * 1997-03-27 1999-06-22 Millenium Pharmaceuticals, Inc. Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
US5900420A (en) * 1997-06-19 1999-05-04 Cole; William L. Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine
US6470933B1 (en) * 1998-03-09 2002-10-29 Pirelli Pneumatici S.P.A. Tire containing at least part of an electrical current generator intended for the supply of sensors and/or other electrical devices present within the tire, and method for manufacture the said tire
FR2781671A1 (fr) * 1998-07-28 2000-02-04 Synthelabo Compositions pharmaceutiques contenant un inhibiteur de la recapture de la serotonine et leur application en therapeutique
TW518218B (en) * 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
EP1612563A3 (en) * 2001-09-11 2009-12-09 JTEKT Corporation Magnetic pulser ring
FR2844591B1 (fr) * 2002-09-13 2005-04-15 Arvinmeritor Light Vehicle Sys Dispositif de determination du deplacement d'un arbre

Also Published As

Publication number Publication date
CN101869565A (zh) 2010-10-27
EP1185272B1 (en) 2004-04-07
EP1736158A2 (en) 2006-12-27
EP1410800B1 (en) 2006-08-23
WO2000072832A3 (en) 2001-12-20
AU771778B2 (en) 2004-04-01
HUP0201275A2 (en) 2002-08-28
JP4884588B2 (ja) 2012-02-29
EP1736158B1 (en) 2009-08-05
CY1105750T1 (el) 2010-12-22
US7642261B2 (en) 2010-01-05
US20100063062A1 (en) 2010-03-11
ATE263564T1 (de) 2004-04-15
HK1048444B (zh) 2005-12-09
EP1185272A2 (en) 2002-03-13
NO322120B1 (no) 2006-08-14
NO20015746D0 (no) 2001-11-26
US20050113386A1 (en) 2005-05-26
US6900212B1 (en) 2005-05-31
HU229059B1 (en) 2013-07-29
DK1185272T3 (da) 2004-08-09
CA2372668A1 (en) 2000-12-07
SI1410800T1 (sl) 2007-02-28
TW518218B (en) 2003-01-21
TR200103361T2 (tr) 2002-05-21
ES2271707T3 (es) 2007-04-16
DK1410800T3 (da) 2006-12-27
JP2011148799A (ja) 2011-08-04
PL200490B1 (pl) 2009-01-30
US7371756B2 (en) 2008-05-13
HUP0201275A3 (en) 2004-04-28
CA2372668C (en) 2009-11-03
PT1736158E (pt) 2009-11-11
ES2330774T3 (es) 2009-12-15
DE60030338T2 (de) 2007-08-16
ATE337008T1 (de) 2006-09-15
EP1410800A1 (en) 2004-04-21
SK287851B6 (sk) 2012-01-04
CY1109472T1 (el) 2012-05-23
ES2219342T3 (es) 2004-12-01
AU5066300A (en) 2000-12-18
NO324230B1 (no) 2007-09-10
SK16462001A3 (sk) 2002-02-05
KR20020008847A (ko) 2002-01-31
BR0010948A (pt) 2002-04-23
UA74337C2 (uk) 2005-12-15
ZA200110485B (en) 2003-06-30
US20080119484A1 (en) 2008-05-22
CA2615271C (en) 2011-02-15
WO2000072832A2 (en) 2000-12-07
CZ20014226A3 (cs) 2002-03-13
CN1679577A (zh) 2005-10-12
CZ295623B6 (cs) 2005-09-14
DE60009697T2 (de) 2005-04-14
PT1410800E (pt) 2007-01-31
JP2003500441A (ja) 2003-01-07
IL146707A (en) 2007-06-03
ATE438399T1 (de) 2009-08-15
DE60030338D1 (de) 2006-10-05
PL199650B1 (pl) 2008-10-31
MXPA01012172A (es) 2002-07-22
SI1185272T1 (en) 2004-12-31
DE60009697D1 (de) 2004-05-13
NO20015746L (no) 2001-11-26
RU2237477C2 (ru) 2004-10-10
CA2615271A1 (en) 2000-12-07
EP1736158A3 (en) 2007-01-03
AR024112A1 (es) 2002-09-04
IL146707A0 (en) 2002-07-25
CA2694866A1 (en) 2000-12-07
PT1185272E (pt) 2004-08-31
DE60042710D1 (de) 2009-09-17
HK1048444A1 (en) 2003-04-04
PL199516B1 (pl) 2008-09-30
CN1198618C (zh) 2005-04-27
DK1736158T3 (da) 2009-11-02
PL352373A1 (en) 2003-08-25
MY135627A (en) 2008-05-30
CN1361692A (zh) 2002-07-31
KR100683367B1 (ko) 2007-02-15

Similar Documents

Publication Publication Date Title
NO324230B1 (no) Anvendelse av 1- [4-(5-cyanindol-3yl)butyl ]-4-(2-karbamoylbenzofuran-5-yl)-piperazin og dets fysiologisk akseptable salter til fremstilling av medikamenter for behandling av bipolare forstyrrelser og mani
NO2015009I1 (no) Nintedanib, tautomere og salter derav, spesielt Nintedanib og fysiologiske akseptable salter derav, spesielt Nintedanib esilat; 3-Z-[l-(4-(N-((4-metylpiperazin-1-yl)-metylkarbonyl)-N-metylamino)- anilino)-1-fenylmetylen]-6-metoksykarbonyl-2-indolinon - Se blant annet kravene 1, 2, 5 (t) og 6 i basispatentet
NO305908B1 (no) Enantiomerer av 1-[(4-klorfenyl)fenylmethyl]-4-[(4-methylfenyl)sulfonyl]piperazin og fremgangsmåte for fremstilling av disse
PL372996A1 (en) 3-z-[1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl)-n-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition
NO341591B1 (no) 3-Z-[1-(4-(N-((4-metyl-piperazin-1-yl)-metylkarbonyl)-N-metyl-amino)-anilino)-1-fenyl-metylen]-6-metoksykarbonyl-2-indolinon, tautomerene, diastereomerene, enantiomerene, blandinger derav og saltene derav, og i kombinasjon med en ytterligere farmakologisk aktiv substans, for anvendelse i forebygging eller behandling av fibrose ved revmatoid artritt
MXPA04001209A (es) Farmaco con efecto neuroprotector.
NO20035116D0 (no) 4-(fenylpiperidin-4-yliden-metyl)-benzamidderivater og deres anvendelse forbehandling av smerte, angst eller gastrointestinale forstyrrelser
CY1112878T1 (el) Νεο αλας βενζοϋλογονανιδινης
NO20035115D0 (no) 4-(fenylpiperidin-4-yliden-metyl)-benzamidderivater og deres anvendelse forbehandling av smerte, angst eller gastrointestinale forstyrrelser
ZA200309557B (en) Novel crystalline forms of 4-[4-[4-(hydroxydiphenylmethy)-1-piperindinyl]-1-hydroxybutyl]-alpha, alpha-dimethylbenzene acetic acid and its hydrochloride.
NO20035117D0 (no) 4-(fenylpiperidin-4-yliden-metyl)-benzamidderivater og deres anvendelse forbehandling av smerte, angst eller gastrointestinale forstyrrelser
NO20024291L (no) Ny anvendelse av (R)-(-)-2[5-(4-fluorfenyl)-3- pyridylmetylaminometyl]kroman og dets fysiologisk akseptablesalter
NO20035118D0 (no) 4-(fenylpiperidin-4-yliden-metyl)-benzamidderivater og deres anvendelse forbehandling av smerte, angst eller gastrointestinale forstyrrelser
MY137876A (en) Pharmaceutical compound
HUP0401039A3 (en) Process for the preparation of (3-cyano-1h-indol-7-yl)(4-(4-fluorophenethyl)piperazin-1-yl)-methanone and salts thereof
ATE330605T1 (de) Piperidin-2,6-dionpamoat-salze und ihre verwendung zur behanldung von stressbedingten affektiven st rungen
DK1293506T3 (da) Nye 1-[1-(hetero)aryl-1-perhydroxyalkylmethyl]-piperazin forbindelser, fremgangsmåde til deres fremstilling og lægemidler indeholdende disse forbindelser
NO995894D0 (no) 2-(4-(4-(4,5-diklor-2-metylimidazol-1-yl)butyl)-1-piperazinyl)-5-fluorpyrimidin, fremstilling og terapeutisk anvendelse
SI1353906T1 (en) Process for the preparation of (3-cyano-1h-indol-7-yl)(4-(4-fluorophenethyl)piperazin-1-yl)-methanone and salts thereof
TH57869A (th) การใช้ในทางใหม่ของ 1-[4-(5-ไซยาโนอินดอล-3-อิล)บิวทิล]-4-(2-คาร์บาโมอิลเบนโซฟูแรน-5-อิล)พิเพอราซีน และเกลือของสารดังกล่าวซึ่งเป็นที่ยอมรับทางสรีรวิทยา
AU2003209521A1 (en) Use of 4-(4-methylpiperazin-1-ylmethyl)-n(4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl)-benzamide for treating seminomas
NO20013498D0 (no) 1-(Metylpyridin-3-yl)-2-[4-(metylsulfonyl)fenyl]etanon og fremgangsmåte for dets fremstilling

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees